XTSEMDNA
Market cap100mUSD
Dec 23, Last price
1.84CAD
1D
7.60%
1Q
-6.12%
IPO
-31.85%
Name
Medicenna Therapeutics Corp
Chart & Performance
P/E
92.98
P/S
—
EPS
0.02
Div Yield, %
0.00%
Shrs. gr., 5y
22.09%
Rev. gr., 5y
%
Revenues
0k
Net income
2m
P
CFO
-13m
L-46.33%
Earnings
Feb 12, 2025
Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 16,298 | 22,436 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (16,298) | (22,436) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (11,595) | 69 | |||||||
Tax Rate | |||||||||
NOPAT | (4,703) | (22,505) | |||||||
Net income | 1,547 -106.83% | (22,646) 31.79% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 24,760 | 3,509 | |||||||
BB yield | -43.46% | -3.92% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,672 | ||||||||
Net debt | (33,596) | (20,535) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (12,657) | (23,584) | |||||||
CAPEX | |||||||||
Cash from investing activities | 10,050 | ||||||||
Cash from financing activities | 24,760 | 3,878 | |||||||
FCF | (4,468) | (22,708) | |||||||
| Balance | |||||||||
Cash | 33,596 | 20,535 | |||||||
Long term investments | |||||||||
Excess cash | 33,596 | 20,535 | |||||||
Stockholders' equity | 20,000 | 12,909 | |||||||
Invested Capital | 12,646 | 7,926 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 64,736 | 54,287 | |||||||
Price | 0.88 -46.67% | 1.65 -67.71% | |||||||
Market cap | 56,968 -36.40% | 89,573 -64.70% | |||||||
EV | 23,372 | 69,038 | |||||||
EBITDA | (16,294) | (22,398) | |||||||
EV/EBITDA | |||||||||
Interest | 69 | ||||||||
Interest/NOPBT | |||||||||